Cerecor's CERC-803 Nabs US Orphan Drug Tag In Rare Immunodeficiency Disorder

by Vandana Singh, Benzinga Editor

February 2, 2021 9:12 AM | 1 min read | Make a Comment

The FDA has designated Fast Track status to Cerecor Inc's (NASDAQ: CERC) CERC-803 for the treatment of Leukocyte Adhesion Deficiency Type 2 (LAD-II), a rare congenital disorder due to mutations in the SLC35C1 gene, and characterized by frequent infections, persistent leukocytosis (abnormally high level of white blood cells), and mental & growth retardation.
Fast Track tag provides more frequent interaction with the FDA and a rolling review of the marketing application.
The company expects to initiate a pivotal trial of CERC-803 in LAD-II in the first half of 2021, with topline data anticipated in the second half of 2021.
Price Action: CERC is higher by 1.27% at $3.19 in the pre-market session on the last check Tuesday.

Posted In: Biotech News Penny Stocks FDA General Immunodeficiency Leukocyte Adhesion Deficiency Orphan Drug Designation

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.